Vertex Pharmaceuticals Incorporated vs Waste Management, Inc. — how do they compare? Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B), while Waste Management, Inc. trades at $209.04 (market cap $83.52B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Waste Management, Inc. pays a 1.81% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Waste Management, Inc. for 130 Days on average.
| VRTX | WM | |
|---|---|---|
Market Cap | $128.16B | $83.52B |
Volume | 806,603 | 2,257,928 |
Sector | Health | Industrials |
52-Week High | $557.96 | $246.51 |
52-Week Low | $407.37 | $196.77 |
Typical Hold Time | 120 Days | 130 Days |
Enterprise Value | $122.29B | $106.32B |
Dividend Yield | — | 1.81% |
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
WM trades at $210.10, up 1.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with $25.2B revenue, 11.12% net margin, and robust cash flow generation. Recent earnings show two beats out of three quarters, while analyst consensus remains strongly positive with 57% buy ratings and no sell recommendations.
WM presents a compelling long-term investment with defensive business model and consistent profitability, though elevated debt levels and valuation multiples require monitoring. The stock offers dividend income with recent $0.95 payout, supported by pricing power and network scale advantages in the essential waste management industry.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →